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[CI], 0.57 to 0.83) for the first 21 days, 1.00 
(95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 
(95% CI, 0.18 to 0.82) for 61 to 90 days. We also 
await results of trials such as POINT and 
TARDIS for confirmation of these results in 
non-Chinese populations.
We agree with Jeong that there may be impor-
tant differences according to the patients’ eth-
nicity and environment that limit the generaliz-
ability of our results, and we await the results of 
future clinical trials.
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Figure 1. Scatter Plot of the Change in Creatinine Level 
in Relation to the Delay before the Administration  
of Eculizumab.
The change in the creatinine level from baseline to  
64 weeks (see section 4 in the Supplementary Appendix, 
available with the full text of the article by Legendre  
et al. at NEJM.org) and the delay before the adminis-
tration of eculizumab (section 2 in the Supplementary 
Appendix of the article) are shown. For all included pa-
tients (two patients with data that were measured only 
at baseline and one patient who received continuous 
hemodialysis were excluded), the correlation coefficient 
was −0.51 (P=0.06). Exclusion of the outlier at the ex-
treme right side of the figure yields a correlation coeffi-
cient of −0.20 (P=0.50). Each dot represents one patient.
Eculizumab in Atypical Hemolytic–Uremic Syndrome
To the Editor: With regard to the article by 
Legendre et al. (June 6 issue)1: assessment of the 
37 patients with atypical hemolytic–uremic syn-
drome is difficult, since the process of selection 
seems opaque, particularly for the 20 patients in 
trial 2. It would have been beneficial to have 
these patients undergo randomization, given the 
fluctuating, relapsing nature of the underlying 
disease. In trial 1, a shorter delay before admin-
istration of the first dose of eculizumab was re-
ported to result in a better recovery of renal func-
tion. My colleagues and I evaluated these data 
with consideration of the delay before adminis-
tration of eculizumab and of the change in creat-
inine values; our findings provided a different 
answer (Fig. 1). Omitting an outlier with a delay 
of 96 days, we found a correlation coefficient of 
−0.20 (P = 0.50).
The article states, “atypical hemolytic–uremic 
syndrome is a genetic, life-threatening, chronic 
disease of complement-mediated thrombotic 
microangiopathy,” yet 24 to 30% of the study 
patients had no proven genetic disease, and proof 
of ongoing complement activation was lacking, 
except for the alleged effect of eculizumab. 
Methods to detect ongoing complement activa-
tion in patients with this rare condition are be-
ing developed2; 20% of these patients are report-
ed to be hematologically normal at presentation.3 
Not all patients with atypical hemolytic–uremic 
syndrome have a straightforward response to 
eculizumab, and explanations other than com-
plement activation may be relevant.4,5
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To the Editor: We have some concerns about 
the use of eculizumab for the treatment of atypi-
cal hemolytic–uremic syndrome.
Our first concern is the use of the EuroQol 
Group 5-Dimension Self-Report Questionnaire 
(EQ-5D) scale to measure health-related quality 
of life. After reading the relevant cited studies,1,2 
we were still unable to determine how the authors 
came to the conclusion that a 0.06 change on the 
scale was clinically important, and we would 
like to know how the number was derived.
Second, the authors reported a significant 
reduction in the number of outcome events 
(plasma exchange or infusion, dialysis, or both) 
from approximately one event to no events per 
day, but we would like to see the absolute num-
bers of the end points that make up this com-
posite. In particular, which component of the 
composite drove the outcome?
Finally, we are concerned that the definition 
of progressive thrombotic microangiopathy in 
the first study preferentially selected for patients 
who would have the largest increase in the plate-
let count after receiving therapy. Were any other 
signs or symptoms considered for the definition 
of progressive thrombotic microangiopathy, or 
were only platelets used?
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To the Editor: In their study of eculizumab 
treatment for atypical hemolytic–uremic syn-
drome, Legendre et al. used a fixed-dose sched-
ule without adjustment for patient weight. We re-
cently administered this regimen to a patient who 
weighed 95 kg. Despite treatment initiated with 
the first episode of atypical hemolytic–uremic 
syndrome, he had an incomplete hematologic re-
sponse and remained dependent on dialysis, even 
though a kidney biopsy performed just before 
treatment initiation did not show signs of irre-
versible damage. Drug monitoring revealed a 
trough level of 71.2 µg per milliliter, which was 
clearly below the level reported in all study pa-
tients, and residual serum complement activity 
was 12% at day 14 after a 1200-mg dose. I suspect 
that insufficient eculizumab dosing due to a high 
body weight may have contributed to the lack of 
renal recovery in our patient, and I doubt wheth-
er one eculizumab dose fits all patients. Unfortu-
nately, because Legendre et al. did not report on 
patient weights, generalizability of the reported 
dosing scheme remains unclear. Did achieved 
drug levels inversely correlate with patient 
weight, and was there a trend toward a reduced 
treatment response in patients with high body 
weight, low eculizumab trough levels, or both?
Andreas D. Kistler, M.D.
University Hospital Zurich 
Zurich, Switzerland 
andreas.kistler@usz.ch
Dr. Kistler reports receiving travel fees from Alexion Pharma-
ceuticals. No other potential conflict of interest relevant to this 
letter was reported.
DOI: 10.1056/NEJMc1308826
To the Editor: Though Legendre et al. report 
that the use of eculizumab resulted in increases 
in the platelet count and improved renal function 
in patients with atypical hemolytic–uremic syn-
drome, it is crucial to explore the most appropri-
ate dose, dosage intervals, and duration of treat-
ment to reduce the enormous financial burden of 
this therapy.
Eculizumab blocks the cleavage of the C5 
complement protein to C5a and C5b, and it pre-
vents the generation of the proinflammatory 
peptide C5a and the membrane-attack complex 
C5b-9. Traditional markers of thrombotic micro-
angiopathy, such as lactate dehydrogenase or 
haptoglobin levels, may not be sensitive enough 
to determine whether the terminal complement 
pathway is adequately blocked. Monitoring of 
complement blockade may be used to adjust the 
dose or the interval between doses of eculizu-
mab therapy to the necessary minimum and may 
lead to cost reduction. Although inhibition of 
complement activity is shown in Figure 2D of 
the article, is the method useful in daily clinical 
practice? We would be grateful if the authors 
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could share laboratory markers for assessing the 
degree of complement blockade.
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The Authors Reply: Ring questions the inclu-
sion of patients without identified complement 
gene mutations, as well as the single-group de-
sign and the effects of earlier intervention. Ac-
cumulating evidence provides support for the 
genetic basis of atypical hemolytic–uremic syn-
drome. The number of identified complement 
mutations has increased from 109 in 2008 (the 
year of the trial initiation) to 604 in 2013. No 
mechanism beyond complement dysregulation 
has been proposed to explain the pathogenesis of 
atypical hemolytic–uremic syndrome in adult pa-
tients. Given the chronic, progressive, life-threat-
ening nature of atypical hemolytic–uremic syn-
drome and the unpredictable risk of permanent 
end-organ damage among patients treated with 
plasma exchange, infusion, or both, randomiza-
tion was considered to be neither possible nor 
ethical. Long-term plasma exchange, infusion, 
or both are associated with substantial morbidi-
ty.1-3 Trial 2 was designed on the basis of data on 
patients receiving such long-term treatment. The 
admission criteria and baseline characteristics of 
the patients in both trials were included in the 
article. Further, earlier intervention led to sig-
nificantly greater improvements in the estimated 
glomerular filtration rate, as shown by an analy-
sis of variance with appropriate correction.
Amadio and Tejani question the use of the 
EQ-5D scale in assessing quality of life. The 
minimally important difference of 0.06 was cho-
sen after consultation with leading experts.4 
With regard to the end points in both trials: all 
components of the composite end points showed 
improvement and contributed equally to the re-
sults. In trial 1, patients with progressive throm-
botic microangiopathy at screening included 
patients with decreased platelet counts despite 
four or more sessions of plasma exchange or in-
fusion in the previous week, thrombotic thrombo-
cytopenia, microangiopathic hemolysis, and in-
creased creatinine levels, as detailed in the article.
Kistler queries whether drug levels inversely 
correlated with weight and affected outcomes. 
Across both trials, five patients weighed more 
than 90.0 kg (mean, 96.4 kg; median, 104.0 kg; 
range, 90.2 to 127.3 kg). Of these patients, eculiz-
umab concentrations were consistently greater 
than 50 µg per milliliter in four patients. Most 
trial end points were met; this showed sustained 
control of the thrombotic microangiopathy.
Tanimoto et al. call for monitoring of com-
plement levels to decrease the dosage of eculizu-
mab, the dosage interval, and the duration of 
treatment. One study showed that treatment 
regimens for atypical hemolytic–uremic syndrome 
that deviate from dosing approved by the Food 
and Drug Administration may lead to complica-
tions and rapid progression to end-stage renal 
disease.3 We agree that markers such as the lac-
tate dehydrogenase level, haptoglobin level, and 
platelet count are insufficiently sensitive for mon-
itoring purposes, as evidenced by significant 
renal improvement in trial 2 (which included pa-
tients with a normal baseline lactate dehydroge-
nase level and platelet count). However, the lack 
of standardization and validation of available 
complement assays currently makes them unsuit-
able for clinical use. Given the risks of disease 
progression, the study dosing regimen was de-
signed by both investigators and regulatory agen-
cies to ensure that 95% of patients or more had 
complete and sustained terminal complement 
inhibition, even during episodes of increased 
complement activity (e.g., infection or surgery).
Christophe M. Legendre, M.D.
Hôpital Necker 
Paris, France 
christophe.legendre@nck.aphp.fr
Christoph Licht, M.D.
Hospital for Sick Children 
Toronto, ON, Canada
Chantal Loirat, M.D.
Hôpital Robert-Debré 
Paris, France
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. George JN, Terrell DR, Swisher KK, Vesely SK. Lessons 
learned from the Oklahoma Thrombotic Thrombocytopenic 
Purpura–Hemolytic Uremic Syndrome Registry. J Clin Apher 
2008;23:129-37.
2. George JN. How I treat patients with thrombotic thrombo-
cytopenic purpura: 2010. Blood 2010;116:4060-9. [Erratum, Blood 
2011;117:5551.]
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on February 14, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;14 nejm.org october 3, 20131380
3. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, 
Ryckelynck JP, Hurault de Ligny B. Eculizumab: safety and effi-
cacy after 17 months of treatment in a renal transplant patient 
with recurrent atypical hemolytic-uremic syndrome: case report. 
Transplant Proc 2010;42:4353-5.
4. Pickard AS, Neary NP, Cella D. Estimation of minimally im-
portant differences in EQ-5D and VAS scores in cancer. Health 
Qual Life Outcomes 2007;5:70. [Erratum, Health Qual Life Out-
comes 2010;8:4.]
DOI: 10.1056/NEJMc1308826
Mental Health and the Global Agenda
To the Editor: Becker and Kleinman (July 4 is-
sue)1 highlight the burden of mental diseases 
worldwide. Major concerns are for people living 
in less-developed countries (because of the low 
level of resources devoted to neuropsychiatric ill-
nesses) and for young people (because of the dif-
ficulty accessing mental care).
We would like to emphasize the enormous 
suffering associated with mental disorders in 
older people. The prevalence of mental diseases 
in older people has increased dramatically in the 
past decades, not only because of aging itself 
(e.g., Alzheimer’s disease), but also because of 
new emotional and sociodemographic situations 
to which the elderly are exposed.2 Moreover, 
disorders such as depression and dysthymia of-
ten become chronic, and the link between men-
tal and physical health (ultimately leading to 
disability) is extremely strong.3 Finally, the use 
of psychotropic medications without fair evidence 
of safety, efficacy, and effectiveness in persons 
who are already receiving many other medica-
tions is fraught with danger. Training primary 
care clinicians in the care of elderly patients with 
mental illness should be a priority.
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To the Editor: In their article, Becker and 
Kleinman articulate the critical steps needed to 
improve global mental health care. One of us is a 
Ghanaian medical student, and we would re-
spectfully add that persons involved in the dis-
course on global mental health also need to en-
gage indigenous mental health care systems. 
These systems, which fall outside the hegemonic 
discourse of Western psychiatry, include tradi-
tional healers and faith-based practitioners. In 
Ghana, it is estimated that there are 45,000 tra-
ditional “healers” — far more than there are psy-
chiatrists, psychologists, social workers, and 
mental health nurses.1 These indigenous forms 
of healing are widely used, in part, because they 
operate within ingrained cultural beliefs about 
mental illnesses,2 and although there is limited 
research, there is some evidence that traditional 
healers are effective in offering certain mental 
health services.3 Although legitimate concerns 
have been raised about human rights abuses and 
the scientific validity of forms of treatment in 
traditional medicine, these caregivers shoulder a 
considerable burden of care delivery and offer an 
important avenue through which capacity can be 
developed, stigma can be reduced, and quality 
can be improved.
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The Authors Reply: Marengoni and Pecorelli 
raise an important point about the large and 
growing mental health burden in older persons. 
Indeed, the formidable burden imposed by Alz-
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